Novartis: Multiple Sclerosis trials

The registry lists 107 Multiple Sclerosis studies with Novartis as lead sponsor. 9 are open to participants now and 46 have results posted.

Phase 1 3Phase 2 15Phase 3 24Phase 4 26No phase 42(a study in two phases counts in both)

Studies

Page 1 of 2. Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study Comparing Effectiveness of Kesimpta® (Ofatumumab) Versus Ocrevus® (Ocrelizumab) in Real-world PracticeRecruitingNCT07779460
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple SclerosisRecruitingNCT07225504Phase 3
• Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.RecruitingNCT06846281Phase 3
• Kesimpta (Ofatumumab) in Greek Multiple Sclerosis Patients - an Observational StudyRecruitingNCT06486779
• Kesimpta Pregnancy and Infant Safety Study Using Real World DataRecruitingNCT06156683
• Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational StudyRecruitingNCT05809986
• Kesimpta (Ofatumumab) Pregnancy RegistryRecruitingNCT05634967
• A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple SclerosisRecruitingNCT05344469
• Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With MayzentRecruitingNCT04933552
• Study of Efficacy and Safety of Ofatumumab in Relapsing Multiple Sclerosis (RMS) Patients in ChinaCompletedNCT05199571Phase 4Results posted
• Study to Assess the Effect of Ofatumumab in Treatment Naïve, Very Early RRMS Patients Benchmarked Against Healthy Controls.CompletedNCT05084638Phase 4Results posted
• A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With OfatumumabTerminatedNCT04878211Phase 4Results posted
• Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) PatientsCompletedNCT04667949Phase 4Results posted
• A Multicenter Study to Assess Response to Influenza Vaccine in Multiple Sclerosis Participants Treated With OfatumumabCompletedNCT04667117Phase 4Results posted
• A Single Arm Study Evaluating the Efficacy, Safety and Tolerability of Ofatumumab in Patients With Relapsing Multiple SclerosisCompletedNCT04486716Phase 3Results posted
• An Open-label Study Evaluating Ofatumumab Treatment Effectiveness and PROs in Subjects With RMS Transitioning From Fumarate-based RMS Approved Therapies or Fingolimod to OfatumumabCompletedNCT04353492Phase 3Results posted
• Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS PatientsCompletedNCT03623243Phase 3Results posted
• A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS PatientsCompletedNCT03560739Phase 2Results posted
• A Study of Immune Phenotype Biomarkers in Patients With Relapsing Multiple Sclerosis (RMS) After Treatment With 0.5mg FingolimodCompletedNCT03257358Phase 4Results posted
• Efficacy and Safety of Ofatumumab Compared to Placebo in Patients With Relapsing Multiple Sclerosis Followed by Extended Treatment With Open-label OfatumumabCompletedNCT03249714Phase 2Results posted
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple Sclerosis.CompletedNCT02792231Phase 3Results posted
• Efficacy and Safety of Ofatumumab Compared to Teriflunomide in Patients With Relapsing Multiple SclerosisCompletedNCT02792218Phase 3Results posted
• Follow up Study of Patients on Fingolimod Who Were Enrolled in the Original Biobank Study (CFTY720DDE01)CompletedNCT02720107Phase 4Results posted
• Effect of Fingolimod on NeurodegenerationTerminatedNCT02575365Phase 4Results posted
• Long-term Follow-up of Fingolimod Phase II Study PatientsCompletedNCT02307838Phase 4Results posted
• Long-term, Open-label, Multicenter Study Assessing Long-term Cardiovascular RisksCompletedNCT02232061Phase 4Results posted
• A Study to Assess the Effect of a Single Infusion of VAY736 on Disease Activity in Patients With Relapsing-remitting Multiple SclerosisTerminatedNCT02038049Phase 2Results posted
• Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingNCT01892722Phase 3Results posted
• Efficacy and Safety of AIN457 (Secukinumab) in Patients With Relapsing Multiple SclerosisTerminatedNCT01874340Phase 2Results posted
• A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®CompletedNCT01705236Phase 4Results posted
• STudy to vAlidate telemetRic ECG Systems for firsT Dose Administration of Fingolimod (START)CompletedNCT01585298Phase 4Results posted
• A 12 -Month, Open-label, Multi-center Study to Explore the Health Outcomes of FTY720CompletedNCT01578330Phase 4Results posted
• Phase Ib Study to Evaluate MOR103 in Multiple SclerosisCompletedNCT01517282Phase 1/2Results posted
• Disease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodTerminatedNCT01499667Phase 3Results posted
• Efficacy of Fingolimod in de Novo Patients Versus Fingolimod in Patients Previously Treated With a First Line Disease Modifying TherapyCompletedNCT01498887Phase 4Results posted
• Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01497262Phase 3Results posted
• Effect of Physical ACtivity in Fingolimod Treated patiEnts (PACE) With Relapsing-remitting Multiple SclerosisTerminatedNCT01490840Phase 4Results posted
• Combination of Antidepressants and Fingolimod Relapsing-remitting Multiple Sclerosis (RRMS) Patients With DepressionTerminatedNCT01436643Phase 4Results posted
• A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01433250Phase 2Results posted
• Fingolimod Versus Interferon Beta 1b in Cognitive SymptomsCompletedNCT01333501Phase 4Results posted
• Patients With Relapse Remitting Multiple Sclerosis (RRMS): Candidates for MS Therapy ChangeCompletedNCT01317004Phase 4Results posted
• A 6-month, Randomized, Open-label, Patient OutComes, Safety and Tolerability Study of Fingolimod (FTY720) 0.5 mg/Day vs. Comparator in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01216072Phase 4Results posted
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple SclerosisCompletedNCT01201356Phase 3Results posted
• Effect of Treatment With Fingolimod on the Immune Response Following Seasonal Flu Vaccination and Tetanus Booster Injection in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT01199861Phase 3Results posted
• Long-term Safety, Tolerability and Efficacy of BAF312 Given Orally in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT01185821Phase 2Results posted
• Zoledronic Acid in MS-patients With OsteoporosisTerminatedNCT01166178Phase 3Results posted
• Rivastigmine in Multiple Sclerosis Patients With Cognitive ImpairmentTerminatedNCT00881205Phase 4Results posted
• Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00879658Phase 2Results posted
• An Extension Study of the Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing Multiple SclerosisCompletedNCT00670449Phase 2Results posted
• Long-term Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00662649Phase 3Results posted
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple Sclerosis (MS)CompletedNCT00537082Phase 2Results posted
• Efficacy and Safety of Fingolimod (FTY720) in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00355134Phase 3Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis With Optional Extension PhaseCompletedNCT00340834Phase 3Results posted
• Efficacy and Safety of FTY720 in Patients With Relapsing Multiple SclerosisCompletedNCT00333138Phase 2Results posted
• Efficacy and Safety of Fingolimod in Patients With Relapsing-remitting Multiple SclerosisCompletedNCT00289978Phase 3Results posted
• A Study of Disease Modifying Therapy Use in Women With Multiple Sclerosis Before, During, and After PregnancyActive, not recruitingNCT07844070
• A Real-World Study of Ofatumumab in Multiple Sclerosis Patients in Germany and JapanActive, not recruitingNCT07821411
• A Study of Treatment Patterns and Annualized Relapse Rate in Multiple Sclerosis Patients Who Escalate Versus Continue Disease-Modifying Therapies Following RelapseCompletedNCT07743281
• A Real-world Study Comparing the Effectiveness of Ofatumumab and Ocrelizumab Treatment in Multiple Sclerosis PatientsCompletedNCT07566988
• A Study to Evaluate the Real-world Experience and Satisfaction Associated With OfatumumabCompletedNCT07504783
• Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of OfatumumabActive, not recruitingNCT06869785Phase 3
• Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple SclerosisActive, not recruitingNCT06847724Phase 3
• Effectiveness of Ofatumumab in Real-world PracticeCompletedNCT06760624
• Real World Effectiveness, Persistence, Tolerability, and Safety of Ofatumumab in Clinical PracticeCompletedNCT06737419
• Open-label, Multi-center, Phase I/II Study to Assess Safety, Disease Progression and Cellular Kinetics Following YTB323 Administration in Participants With Non-active Progressive Multiple Sclerosis (PMS)Active, not recruitingNCT06675864Phase 1/2
• Multiple Sclerosis Patient Experience on Kesimpta and Ocrevus Subcutaneous FormulationCompletedNCT06668324
• Real-World Persistence and Adherence of Ofatumumab Compared to Self-Injectable and Oral DMTs in Patients With Multiple SclerosisCompletedNCT06644638
• An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple SclerosisActive, not recruitingNCT06617793Phase 1/2
• A Non-interventional Study Evaluating Clinical Utility and Implications on Improved Patient Management of Serum Neurofilament as a Prognostic Marker for Disease Activity in Patients With Relapsing Multiple SclerosisActive, not recruitingNCT06551519
• A Study to Assess COVID-19 Vaccination Immune Response in Multiple Sclerosis Patients Treated With OfatumumabCompletedNCT06460324
• Characteristics, Adherence, and Persistence Among Multiple Sclerosis Patients Treated With Disease-Modifying TherapiesCompletedNCT06459232
• Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple SclerosisActive, not recruitingNCT06444113Phase 4
• ITAKOS - Italian Observation, Multicenter, Prospective Study of Ofatumumab in RRMS PatientsActive, not recruitingNCT06345157
• A Cross-sectional Study to Assess the Effectiveness and Safety of Ofatumumab (Kesimpta®) in Patients With Relapsing Multiple Sclerosis in the Spanish Clinical PracticeCompletedNCT06251986
• Assessment of the Quality of Life of Multiple Sclerosis Patients Treated With Ofatumumab in Real-life in FranceActive, not recruitingNCT06157086
• WOE of Anti-CD20 TherapiesCompletedNCT06121349
• Assessment of Immune Response in Multiple Sclerosis Patients With COVID-19/Vaccination Treated With Ofatumumab and Other Disease Modifying TherapiesCompletedNCT05950308
• Early Versus Late Ofatumumab (Kesimpta®) Use in Austrian RMS-Patients Over 2 YearsActive, not recruitingNCT05776888
• The 'Wearing Off' Effect of DMTCompletedNCT05627271
• Characterization of Early Patients Initiating Ofatumumab for Treatment of Multiple Sclerosis.CompletedNCT05576779
• Study Evaluating Kesimpta® Treatment Effects in Patients With Relapsing Multiple Sclerosis Transitioning From Other TherapiesCompletedNCT05566756
• Risk Perception in Multiple SclerosisCompletedNCT05528666
• A Survey to Evaluate Early Experience From Patient and Care Partner on Injection and Device for KESIMPTA® Indicated for Multiple SclerosisCompletedNCT05334472
• Survey Among Healthcare Professionals and MS Patients to Assess Their Understanding of RMP MaterialsCompletedNCT05301907
• Kesimpta® (Ofatumumab) in Swiss Multiple Sclerosis Patients - an Observational StudyCompletedNCT05285904
• Exploring the Profiles of RMS Patients on Ofatumumab or Ocrelizumab in a Real-World Setting in the GulfCompletedNCT05266469
• Impact of Fingolimod Adherence on OutcomesCompletedNCT05141669
• A Multicenter Study of Continued Current Therapy vs Transition to Ofatumumab After Neurofilament (NfL) ElevationActive, not recruitingNCT05090371Phase 4
• Characterizing the Use of Ofatumumab in a Real World SettingCompletedNCT05090033
• Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg PenCompletedNCT04940065
• Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple SclerosisActive, not recruitingNCT04926818Phase 3
• Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMSCompletedNCT04788615Phase 3
• Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple SclerosisCompletedNCT04676555
• Managed Access Program (MAP) for Patients Diagnosed With Secondary Progressive Multiple Sclerosis With Active DiseaseNo longer availableNCT04540861
• Safety and Efficacy Study of Fingolimod in Taiwanese Adults (≥ 20years) With Relapsing Remitting Multiple SclerosisActive, not recruitingNCT04480853Phase 4
• Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MSActive, not recruitingNCT03650114Phase 3
• Optical Coherence Tomography (OCT) Trial in Multiple SclerosisCompletedNCT02907281
• Safety and Efficacy of Fingolimod in MS Patients in ChinaWithdrawnNCT01941004Phase 3
• Efficacy of 5 Weeks of Treatment With BGG492 in Patients With Spasticity Due to Multiple SclerosisWithdrawnNCT01649050Phase 2
• ENGYNE Exploring Gilenya in Patients With Neutralizing Antibodies Against InterferonWithdrawnNCT01621269Phase 4